Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma-Reference-Cited by-同舟云学术

Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma

Published:2022-01-23 Issue:2 Volume:89 Page:255-265
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Moy Ryan H.^ORCID,Greally Megan,Chou Joanne F.,Li Jia,Desai Avni M.,Chalasani Sree B.,Won Elizabeth,Kelsen David P.,Ilson David H.,Janjigian Yelena Y.,Capanu Marinela,Ku Geoffrey Y.^ORCID

Funder

Arog Pharmaceuticals

National Cancer Institute

Damon Runyon Cancer Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-021-04384-1.pdf

Reference46 articles.

1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https://doi.org/10.3322/caac.21660

2. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF et al (2018) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 4:1553–1568. https://doi.org/10.1001/jamaoncol.2018.2706

3. Codipilly DC, Sawas T, Dhaliwal L et al (2021) Epidemiology and outcomes of young-onset esophageal adenocarcinoma: an analysis from a population-based database. Cancer Epidemiol Biomark Prev 30:142–149. https://doi.org/10.1158/1055-9965.EPI-20-0944

4. Enzinger PC, Burtness BA, Niedzwiecki D et al (2016) CALGB 80403 (alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol 34:2736–2742. https://doi.org/10.1200/JCO.2015.65.5092

5. Bang Y-J, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697. https://doi.org/10.1016/S0140-6736(10)61121-X

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule inhibitors targeting the cancers;MedComm;2022-10-13